1. A combination comprising as component (s) :( a) at least one 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol of formula (I), optionally in form of one of its stereoisomers, in particular enantiomer or diastereomer, a racemate or in form of a mixture of its stereoisomers, in particular enantiomers and / or diastereomers in any mixing ratio, or any corresponding acid addition salt, and (b) at least one antagonist NMDA.2. A combination according to claim 1, characterized in that a compound of formula (I) is selected from the group which includes (1R, 2R) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol, (1S , 2S) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol, (1R, 2S) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol, (1S, 2R) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol, and any of their smes.3. A combination according to claim 2, characterized in that a compound of formula (I) is selected from the group to which the (1R, 2R) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol, (1S, 2S) -3- (3-dimethylamino-1-ethyl-2-methyl- propyl) -phenol, and any of their smes.4. A combination according to claim 2 or 3, characterized in that the compound of formula (I) is (1R, 2R) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol of formula (I ), or its acid addition salt, with preference given to acid addition salts gidrohlorida.5. The combination of claim 1, wherein the NMDA-antagonist is selected from the group which includes norvaline (AP5), D-norvaline (D-AP5), 4- (3-phosphono-propyl) -piperazine-2-carboxylic acid (CPP), D- (E) -4- (3-phosphonopropyl-2-enyl) piperazine-2-carboxylic acid (D-SRRen), cis-4- (phosphonomethyl) -2-piperidine carboxylic acid (Selfotel, CGS 19755), SDZ-220581, PD-134705, LY-274614, WAY-126090, kynurenic acid, 7-chloro-kynurenic acid, 7-chloro-tiokinurenovaya acid, 5,7-dichloro-kinurenov1. Комбинация, включающая в качестве компонента(ов):(a) как минимум один 3-(3-диметиламино-1-этил-2-метил-пропил)-фенол формулы
